To support our findings that low expression of FOXF2 is a negative prognostic factor, a prior study demonstrated that patients with stage I NSCLC who had low FOXF2 expression had significantly shorter overall survival compared to patients with high FOXF2 expression40. This evidence concerns the gene FOXF2 and non-small cell lung carcinoma.